| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Celularity Inc. Class A Common Stock$0.8
+0.02 (+3.15%)
Market Cap
36.62 M
EPS
-3.33
P/E Ratio
-0.38 $
Value Trade
165.37 K
SEC Financials
Q4 2025Dilution Risk
Revenue
4.10 M
R&D Expenses
3.35 M
Operating CF
-3.31 M
Total Assets
107.33 M
Total Liabilities
145.39 M
Equity
-38.06 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
6.17 M
Monthly Burn
1.10 M
Runway
4.3 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
180.46 K
52 Week Range
1.01 - 4.35
% held by Insiders
60.04 %
% held by Institutions
7.49 %
Enterprise Value
103.27 M
Total Shares
28.96 M
Short %
2.98 %
Float Shares
7.27 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CELU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Celularity Inc. Class A Common Stock (CELU) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CELU
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CELU
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CELU
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CELU Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CELU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CELU
Jun 4, 2026Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Celularity Inc. and Fountain Life Management have announced the availability of cenplacel-L, a placental-derived cell therapy, for investigational use in Florida. This follows new legislation that allows licensed physicians to utilize certain unapproved therapies. The initiative aims to create a scalable pathway for regenerative medicine, leveraging Celularity's manufacturing capabilities and clinical-grade products.
Read more →-CELU
Jun 3, 2026Celularity Releases CEO Letter to Shareholders
Celularity Inc. has released a letter from CEO Robert J. Hariri detailing the company's strategic focus on placental-derived cellular therapies, particularly cenplacel-L. The company has streamlined operations and out-licensed its biomaterials business to strengthen its financial position. Despite challenges in the capital markets, there is strong physician interest in cenplacel-L, positioning Celularity for potential growth in the regenerative medicine sector.
Read more →-CELU
Jun 3, 2026Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity Inc. has appointed Rick Gonzalez as Chief Commercial Officer to enhance its global commercial strategy. His experience in biotechnology and medical technology is expected to drive growth for the company's cenplacel-L and Lifebank offerings. The appointment comes as Celularity aims to expand access to its regenerative therapies amid increasing physician interest.
Read more →-CELU
May 29, 2026Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Inc. received a notice from Nasdaq regarding its delayed filing of the Form 10-Q for Q1 2026, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Despite the notice, trading of CELU stock remains unaffected.
Read more →-CELU
May 4, 2026Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Celularity Inc. has filed its Form 10-K for the fiscal year ending December 31, 2025, regaining compliance with Nasdaq's listing requirements. The company has undertaken strategic initiatives, including the out-licensing of its biomaterials portfolio and a reduction in liabilities by about $13 million. Leadership emphasizes a focused approach towards advancing regenerative medicine and creating long-term value.
Read more →-CELU
Apr 21, 2026Celularity Announces Closing of Transaction with NexGel
Celularity Inc. has completed a transaction with NexGel, where NexGel acquired assets related to Celularity's biomaterials portfolio. The deal, valued at $13.3 million, allows Celularity to focus on its therapeutic pipeline while potentially earning additional milestone payments. This transaction also helps Celularity retire significant debt, enhancing its financial position.
Read more →-CELU
Apr 20, 2026Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. received a notice from Nasdaq for not filing its Form 10-K for the fiscal year ending December 31, 2025. The company has 60 days to submit a compliance plan and may receive an extension of up to 180 days to regain compliance. Despite the notice, trading of its stock continues without immediate effect.
Read more →-CELU
Feb 10, 2026Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Celularity Inc. announced it has received $12.2 million from the sale of its unused New Jersey net operating losses and research tax credits. This transaction, facilitated by the New Jersey Economic Development Authority, provides the company with non-dilutive capital to enhance liquidity and support its regenerative medicine initiatives. The funds will aid in advancing their cell therapies targeting aging mechanisms.
Read more →-CELU
Dec 29, 2025Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Celularity's CEO, Dr. Robert J. Hariri, expressed support for the CMS's withdrawal of skin substitute Local Coverage Determinations (LCDs), which would have affected other companies' products. Despite the withdrawal, Celularity's Biovance® and Biovance 3L remain eligible for Medicare coverage. The new Medicare payment policy for skin substitutes will still apply, ensuring reimbursement at a flat rate.
Read more →Competitive Position
How CELU ranks across every disease it competes inCompetitive Position is a premium feature
See how CELU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial